Guard Medical Inc., a Miami, Florida-based developer of solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions, closed an $11m Series B funding round.
Current investors include Bpifrance and Matignon Investissement et Gestion.
Led by Machiel van der Leest, CEO, Guard Medical is developing solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis. Its NPWT technology originated with NewYork-Presbyterian and Weill Cornell Medicine in response to physician’s identification of unmet needs related to Surgical Site Infections (SSI).
The capital will support commercialization and clinical studies of its (NPWT) dressing NPsealTM for the treatment of closed surgical incisions. NPsealTM is an easy-to-use and cost-effective NPWT surgical dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.
FinSMEs
07/04/2022